Zobrazeno 1 - 10 of 17 pro vyhledávání: '"JP Combal"'
2
Akademický článek
Characteristics of patients with Wilson disease in the United States: An insurance claims database study.
Autor: Daniel-Robin T; Vivet Therapeutics, Paris 75008, France., Kumar P; Clarivate, Noida 201301, Uttar Pradesh, India., Benichou B; Vivet Therapeutics, Paris 75008, France., Combal JP; Vivet Therapeutics, Paris 75008, France. jpcombal@vivet-therapeutics.com.
Publikováno v: World journal of hepatology [World J Hepatol] 2024 May 27; Vol. 16 (5), pp. 791-799.
Zobrazit plný text záznamu
3
Akademický článek
Outcomes of 38 patients with PFIC3: Impact of genotype and of response to ursodeoxycholic acid therapy.
Autor: Gonzales E; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Gardin A; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Almes M; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Darmellah-Remil A; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France., Seguin H; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France., Mussini C; Pathology, Bicêtre Hospital, Assistance Publique - Hôpitaux de Paris, University Paris-Saclay, Le Kremlin-Bicêtre, France., Franchi-Abella S; Pediatric Radiology, Bicêtre Hospital, Assistance Publique - Hôpitaux de Paris, University Paris-Saclay, Le Kremlin-Bicêtre, France., Duché M; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Pediatric Radiology, Bicêtre Hospital, Assistance Publique - Hôpitaux de Paris, University Paris-Saclay, Le Kremlin-Bicêtre, France., Ackermann O; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Thébaut A; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Habes D; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Hermeziu B; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Lapalus M; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Falguières T; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Combal JP; Vivet Therapeutics, Paris, France., Benichou B; Vivet Therapeutics, Paris, France., Valero S; Vivet Therapeutics, Paris, France., Davit-Spraul A; Biochemistry; Bicêtre Hospital, Assistance Publique - Hôpitaux de Paris, University Paris-Saclay, Le Kremlin-Bicêtre, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France., Jacquemin E; Pediatric Hepatology and Liver Transplantation, National Reference Centre for Biliary Atresia and Genetic Cholestasis, FILFOIE, ERN RARE LIVER, France.; Inserm U1193, Hepatinov, University Paris-Saclay, Orsay, France.
Publikováno v: JHEP reports : innovation in hepatology [JHEP Rep] 2023 Jul 13; Vol. 5 (10), pp. 100844. Date of Electronic Publication: 2023 Jul 13 (Print Publication: 2023).
Zobrazit plný text záznamu
4
Akademický článek
Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy.
Autor: Weber ND; Vivet Therapeutics S.L., Pamplona, Spain., Odriozola L; Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Pamplona, Spain., Ros-Gañán I; Vivet Therapeutics S.L., Pamplona, Spain., García-Porrero G; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain., Salas D; Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Pamplona, Spain., Argemi J; Liver Unit, Internal Medicine Department, Clínica Universidad de Navarra and Hepatology Program, CIMA, Universidad de Navarra, Pamplona, Spain.; Division of Medicine, Gastroenterology and Hepatology Department, University of Pittsburgh, Pittsburgh, PA, USA.; Centro de Investigacion Biomedica en Red (CIBER-Ehd), Madrid, Spain., Combal JP; Vivet Therapeutics S.A.S., Paris, France., Kishimoto TK; Selecta Biosciences, Watertown, MA, USA., González-Aseguinolaza G; Vivet Therapeutics S.L., Pamplona, Spain.; Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Pamplona, Spain.
Publikováno v: JHEP reports : innovation in hepatology [JHEP Rep] 2023 Feb 24; Vol. 5 (5), pp. 100713. Date of Electronic Publication: 2023 Feb 24 (Print Publication: 2023).
Zobrazit plný text záznamu
5
Akademický článek
Epidemiology, treatment and burden of Wilson disease in France: A 10-year analysis of the national health insurance database.
Autor: Daniel-Robin T; Vivet Therapeutics, Paris, France. Electronic address: tdaniel@vivet-therapeutics.com., Bénichou B; Vivet Therapeutics, Paris, France., Leboucher C; Creativ-Ceuticals, Lyon, France., Blein C; Creativ-Ceuticals, Lyon, France., Combal JP; Vivet Therapeutics, Paris, France.
Publikováno v: Clinics and research in hepatology and gastroenterology [Clin Res Hepatol Gastroenterol] 2022 Dec; Vol. 46 (10), pp. 101992. Date of Electronic Publication: 2022 Jul 03.
Zobrazit plný text záznamu
6
Akademický článek
Gene Therapy in Combination with Nitrogen Scavenger Pretreatment Corrects Biochemical and Behavioral Abnormalities of Infant Citrullinemia Type 1 Mice.
Autor: Bazo A; Division of Gene Therapy and Regulation of Gene Expression, CIMA, University of Navarra, 31008 Pamplona, Spain., Lantero A; Vivet Therapeutics, S.L., 31008 Pamplona, Spain., Mauleón I; Division of Gene Therapy and Regulation of Gene Expression, CIMA, University of Navarra, 31008 Pamplona, Spain., Neri L; Vivet Therapeutics, S.L., 31008 Pamplona, Spain., Poms M; Department of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland., Häberle J; Division of Metabolism, Children's Research Centre (CRC), University Children's Hospital Zurich, 8091 Zurich, Switzerland., Ricobaraza A; Division of Gene Therapy and Regulation of Gene Expression, CIMA, University of Navarra, 31008 Pamplona, Spain., Bénichou B; Vivet Therapeutics, S.A.S., 75008 Paris, France., Combal JP; Vivet Therapeutics, S.A.S., 75008 Paris, France., Gonzalez-Aseguinolaza G; Division of Gene Therapy and Regulation of Gene Expression, CIMA, University of Navarra, 31008 Pamplona, Spain.; Vivet Therapeutics, S.L., 31008 Pamplona, Spain., Aldabe R; Division of Gene Therapy and Regulation of Gene Expression, CIMA, University of Navarra, 31008 Pamplona, Spain.
Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2022 Nov 29; Vol. 23 (23). Date of Electronic Publication: 2022 Nov 29.
Zobrazit plný text záznamu
7
Akademický článek
High value of 64 Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's disease.
Autor: Murillo O; Gene Therapy and Regulation of Gene Expression Program, Centro de Investigacion Medica Aplicada (CIMA), FIMA, Navarra Institute for Health Research (IdisNA), University of Navarra, Avda Pio XII 55, 31008 Pamplona, Spain., Collantes M; Department of Nuclear Medicine, IdisNA, Clinica Universidad de Navarra, 31008 Pamplona, Spain.; Translational Molecular Imaging Unit, IdisNA, Clinica Universidad de Navarra, 31008 Pamplona, Spain., Gazquez C; Gene Therapy and Regulation of Gene Expression Program, Centro de Investigacion Medica Aplicada (CIMA), FIMA, Navarra Institute for Health Research (IdisNA), University of Navarra, Avda Pio XII 55, 31008 Pamplona, Spain., Moreno D; Gene Therapy and Regulation of Gene Expression Program, Centro de Investigacion Medica Aplicada (CIMA), FIMA, Navarra Institute for Health Research (IdisNA), University of Navarra, Avda Pio XII 55, 31008 Pamplona, Spain., Hernandez-Alcoceba R; Gene Therapy and Regulation of Gene Expression Program, Centro de Investigacion Medica Aplicada (CIMA), FIMA, Navarra Institute for Health Research (IdisNA), University of Navarra, Avda Pio XII 55, 31008 Pamplona, Spain., Barberia M; Gene Therapy and Regulation of Gene Expression Program, Centro de Investigacion Medica Aplicada (CIMA), FIMA, Navarra Institute for Health Research (IdisNA), University of Navarra, Avda Pio XII 55, 31008 Pamplona, Spain., Ecay M; Translational Molecular Imaging Unit, IdisNA, Clinica Universidad de Navarra, 31008 Pamplona, Spain., Tamarit B; Vivet Therapeutics SAS, Paris, France., Douar A; Vivet Therapeutics SAS, Paris, France., Ferrer V; Vivet Therapeutics SAS, Paris, France., Combal JP; Vivet Therapeutics SAS, Paris, France., Peñuelas I; Department of Nuclear Medicine, IdisNA, Clinica Universidad de Navarra, 31008 Pamplona, Spain.; Translational Molecular Imaging Unit, IdisNA, Clinica Universidad de Navarra, 31008 Pamplona, Spain., Bénichou B; Vivet Therapeutics SAS, Paris, France., Gonzalez-Aseguinolaza G; Gene Therapy and Regulation of Gene Expression Program, Centro de Investigacion Medica Aplicada (CIMA), FIMA, Navarra Institute for Health Research (IdisNA), University of Navarra, Avda Pio XII 55, 31008 Pamplona, Spain.; Vivet Therapeutics S.L., Pamplona, Spain.
Publikováno v: Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2022 Jun 09; Vol. 26, pp. 98-106. Date of Electronic Publication: 2022 Jun 09 (Print Publication: 2022).
Zobrazit plný text záznamu
8
Akademický článek
Optimising the IgG-degrading enzyme treatment regimen for enhanced adeno-associated virus transduction in the presence of neutralising antibodies.
Autor: Ros-Gañán I; Vivet Therapeutics S.L. Pamplona Spain., Hommel M; Division of Gene Therapy and Regulation of Gene Expression CIMA University of Navarra Pamplona Spain.; Institute for Sanitary Research (IdiSNA) Pamplona Spain., Trigueros-Motos L; Vivet Therapeutics S.L. Pamplona Spain., Tamarit B; Vivet Therapeutics SAS Paris France., Rodríguez-García E; Division of Gene Therapy and Regulation of Gene Expression CIMA University of Navarra Pamplona Spain.; Institute for Sanitary Research (IdiSNA) Pamplona Spain., Salas D; Division of Gene Therapy and Regulation of Gene Expression CIMA University of Navarra Pamplona Spain.; Institute for Sanitary Research (IdiSNA) Pamplona Spain., Pérez G; Division of Gene Therapy and Regulation of Gene Expression CIMA University of Navarra Pamplona Spain.; Institute for Sanitary Research (IdiSNA) Pamplona Spain., Douar A; Vivet Therapeutics SAS Paris France., Combal JP; Vivet Therapeutics SAS Paris France., Benichou B; Vivet Therapeutics SAS Paris France., Ferrer V; Vivet Therapeutics SAS Paris France., González-Aseguinolaza G; Vivet Therapeutics S.L. Pamplona Spain.; Division of Gene Therapy and Regulation of Gene Expression CIMA University of Navarra Pamplona Spain.; Institute for Sanitary Research (IdiSNA) Pamplona Spain.
Publikováno v: Clinical & translational immunology [Clin Transl Immunology] 2022 Feb 24; Vol. 11 (2), pp. e1375. Date of Electronic Publication: 2022 Feb 24 (Print Publication: 2022).
Zobrazit plný text záznamu
9
Akademický článek
Chemical modification of the adeno-associated virus capsid to improve gene delivery.
Autor: Mével M; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr., Bouzelha M; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr., Leray A; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr.; LUNAM Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques 44322 Nantes France david.deniaud@univ-nantes.fr., Pacouret S; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr., Guilbaud M; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr., Penaud-Budloo M; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr., Alvarez-Dorta D; LUNAM Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques 44322 Nantes France david.deniaud@univ-nantes.fr., Dubreil L; PanTher-UMR 703, INRA-ONIRIS, Atlanpole-Chanterie 44307 Nantes France., Gouin SG; LUNAM Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques 44322 Nantes France david.deniaud@univ-nantes.fr., Combal JP; Vivet Therapeutics SAS Paris France., Hommel M; Gene Therapy and Regulation of Gene Expression Program, CIMA, FIMA, University of Navarra, Navarra Institute for Health Research (IdisNA) Pamplona Spain., Gonzalez-Aseguinolaza G; Vivet Therapeutics SAS Paris France.; Gene Therapy and Regulation of Gene Expression Program, CIMA, FIMA, University of Navarra, Navarra Institute for Health Research (IdisNA) Pamplona Spain., Blouin V; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr., Moullier P; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr., Adjali O; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr., Deniaud D; LUNAM Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques 44322 Nantes France david.deniaud@univ-nantes.fr., Ayuso E; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr.
Publikováno v: Chemical science [Chem Sci] 2019 Dec 09; Vol. 11 (4), pp. 1122-1131. Date of Electronic Publication: 2019 Dec 09.
Zobrazit plný text záznamu
10
Akademický článek
Liver Expression of a MiniATP7B Gene Results in Long-Term Restoration of Copper Homeostasis in a Wilson Disease Model in Mice.
Autor: Murillo O; Gene Therapy and Regulation of Gene Expression Program, CIMA, FIMA, University of Navarra, Navarra Institute for Health Research (IdisNA), Pamplona, Spain., Moreno D; Gene Therapy and Regulation of Gene Expression Program, CIMA, FIMA, University of Navarra, Navarra Institute for Health Research (IdisNA), Pamplona, Spain., Gazquez C; Gene Therapy and Regulation of Gene Expression Program, CIMA, FIMA, University of Navarra, Navarra Institute for Health Research (IdisNA), Pamplona, Spain., Barberia M; Gene Therapy and Regulation of Gene Expression Program, CIMA, FIMA, University of Navarra, Navarra Institute for Health Research (IdisNA), Pamplona, Spain., Cenzano I; Gene Therapy and Regulation of Gene Expression Program, CIMA, FIMA, University of Navarra, Navarra Institute for Health Research (IdisNA), Pamplona, Spain., Navarro I; Department of Chemistry and Soil Sciences, University of Navarra, IdisNA, Pamplona, Spain., Uriarte I; Hepatology Program, CIMA, FIMA, University of Navarra, IdisNA, Pamplona, Spain.; CIBERehd, Instituto de Salud Carlos III, Clinica Universidad de Navarra, Pamplona, Spain., Sebastian V; Department of Chemical Engineering, Aragón Institute of Nanoscience (INA), University of Zaragoza, and Aragon Health Research Institute (IIS Aragon), Zaragoza, Spain.; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, 28029-, Madrid, Spain., Arruebo M; Department of Chemical Engineering, Aragón Institute of Nanoscience (INA), University of Zaragoza, and Aragon Health Research Institute (IIS Aragon), Zaragoza, Spain.; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, 28029-, Madrid, Spain., Ferrer V; Vivet Therapeutics SAS, Paris, France., Bénichou B; Vivet Therapeutics SAS, Paris, France., Combal JP; Vivet Therapeutics SAS, Paris, France., Prieto J; Gene Therapy and Regulation of Gene Expression Program, CIMA, FIMA, University of Navarra, Navarra Institute for Health Research (IdisNA), Pamplona, Spain., Hernandez-Alcoceba R; Gene Therapy and Regulation of Gene Expression Program, CIMA, FIMA, University of Navarra, Navarra Institute for Health Research (IdisNA), Pamplona, Spain., Gonzalez Aseguinolaza G; Gene Therapy and Regulation of Gene Expression Program, CIMA, FIMA, University of Navarra, Navarra Institute for Health Research (IdisNA), Pamplona, Spain.; Vivet Therapeutics SAS, Paris, France.
Publikováno v: Hepatology (Baltimore, Md.) [Hepatology] 2019 Jul; Vol. 70 (1), pp. 108-126. Date of Electronic Publication: 2019 Mar 20.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje